{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T15:08:47Z","timestamp":1776179327580,"version":"3.50.1"},"reference-count":168,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,11,2]],"date-time":"2022-11-02T00:00:00Z","timestamp":1667347200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100010877","name":"Science, Technology and Innovation Commission of Shenzhen Municipality","doi-asserted-by":"publisher","award":["JCYJ20200109142610136"],"award-info":[{"award-number":["JCYJ20200109142610136"]}],"id":[{"id":"10.13039\/501100010877","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["31971268"],"award-info":[{"award-number":["31971268"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021171","name":"Basic and Applied Basic Research Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2019A1515010855"],"award-info":[{"award-number":["2019A1515010855"]}],"id":[{"id":"10.13039\/501100021171","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014857","name":"National Natural Science Foundation of China-Guangdong Joint Fund","doi-asserted-by":"publisher","award":["2020A1515010802"],"award-info":[{"award-number":["2020A1515010802"]}],"id":[{"id":"10.13039\/501100014857","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021171","name":"Basic and Applied Basic Research Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2020A1515110166"],"award-info":[{"award-number":["2020A1515110166"]}],"id":[{"id":"10.13039\/501100021171","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014857","name":"National Natural Science Foundation of China-Guangdong Joint Fund","doi-asserted-by":"publisher","award":["No.2020A1515010802"],"award-info":[{"award-number":["No.2020A1515010802"]}],"id":[{"id":"10.13039\/501100014857","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017610","name":"Shenzhen Science and Technology Innovation Program","doi-asserted-by":"publisher","award":["Grant No. RCYX20200714114643121"],"award-info":[{"award-number":["Grant No. RCYX20200714114643121"]}],"id":[{"id":"10.13039\/501100017610","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017607","name":"Shenzhen Fundamental Research Program","doi-asserted-by":"publisher","award":["JCYJ20180507181654186"],"award-info":[{"award-number":["JCYJ20180507181654186"]}],"id":[{"id":"10.13039\/501100017607","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012226","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","award":["19lgzd45"],"award-info":[{"award-number":["19lgzd45"]}],"id":[{"id":"10.13039\/501100012226","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>The pathogeny of type 1 diabetes (T1D) is mainly provoked by the \u03b2-cell loss due to the autoimmune attack. Critically, autoreactive T cells firsthand attack \u03b2-cell in islet, that results in the deficiency of insulin in bloodstream and ultimately leads to hyperglycemia. Hence, modulating immunity to conserve residual \u03b2-cell is a desirable way to treat new-onset T1D. However, systemic immunosuppression makes patients at risk of organ damage, infection, even cancers. Biomaterials can be leveraged to achieve targeted immunomodulation, which can reduce the toxic side effects of immunosuppressants. In this review, we discuss the recent advances in harness of biomaterials to immunomodulate immunity for T1D. We investigate nanotechnology in targeting delivery of immunosuppressant, biological macromolecule for \u03b2-cell specific autoreactive T cell regulation. We also explore the biomaterials for developing vaccines and facilitate immunosuppressive cells to restore immune tolerance in pancreas.<\/jats:p>","DOI":"10.3389\/fimmu.2022.997287","type":"journal-article","created":{"date-parts":[[2022,11,2]],"date-time":"2022-11-02T14:38:47Z","timestamp":1667399927000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":11,"title":["Leverage biomaterials to modulate immunity for type 1 diabetes"],"prefix":"10.3389","volume":"13","author":[{"given":"Zhangyan","family":"Jing","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yumeng","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaozhou","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Liang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xudong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,11,2]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/s41574-020-00443-4","article-title":"Type 1 diabetes mellitus as a disease of the beta-cell (do not blame the immune system?)","volume":"17","author":"Roep","year":"2021","journal-title":"Nat Rev Endocrinol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/nri2787","article-title":"Immune cell crosstalk in type 1 diabetes","volume":"10","author":"Lehuen","year":"2010","journal-title":"Nat Rev Immunol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3389\/fbioe.2021.662084","article-title":"An overview of engineered hydrogel-based biomaterials for improved beta-cell survival and insulin secretion","volume":"9","author":"Ghasemi","year":"2021","journal-title":"Front bioeng Biotechnol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/ncpendmet1044","article-title":"Continuous glucose monitoring: Long live the revolution","volume":"5","author":"Waldron-Lynch","year":"2009","journal-title":"Nat Clin Pract Endocrinol Metab"},{"key":"B5","doi-asserted-by":"publisher","first-page":"594","DOI":"10.3390\/pharmaceutics11110597","article-title":"Review of advanced hydrogel-based cell encapsulation systems for insulin delivery in type 1 diabetes mellitus","volume":"11","author":"Espona-Noguera","year":"2019","journal-title":"Pharmaceutics"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1089\/dia.2016.2502","article-title":"Continuous glucose monitoring in 2015","author":"Battelino","year":"2016","journal-title":"Diabetes Technol Ther"},{"key":"B7","doi-asserted-by":"publisher","first-page":"e1902004","DOI":"10.1002\/adma.201902004","article-title":"Glucose-responsive insulin and delivery systems: Innovation and translation","volume":"32","author":"Wang","year":"2020","journal-title":"Adv mat"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200007273430401","article-title":"Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen","volume":"343","author":"Shapiro","year":"2000","journal-title":"N Engl J Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.tem.2016.08.007","article-title":"Immune and pancreatic beta cell interactions in type 1 diabetes","volume":"27","author":"Boldison","year":"2016","journal-title":"Trends Endocrinol Metab"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-019-0232-6","article-title":"Treg cell-based therapies: challenges and perspectives","volume":"20","author":"Raffin","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198803173181103","article-title":"Factors associated with early remission of type i diabetes in children treated with cyclosporine","volume":"318","author":"Bougneres","year":"1988","journal-title":"N Engl J Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa043980","article-title":"Insulin needs after cd3-antibody therapy in new-onset type 1 diabetes","volume":"352","author":"Keymeulen","year":"2005","journal-title":"N Engl J Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1021\/acs.biochem.9b00707","article-title":"Anti-cd3 antibody for the prevention of type 1 diabetes: a story of perseverance","volume":"58","author":"Gaglia","year":"2019","journal-title":"Biochemistry"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2015.03.030","article-title":"Immune checkpoint targeting in cancer therapy: Toward combination strategies with curative potential","volume":"161","author":"Sharma","year":"2015","journal-title":"Cell"},{"key":"B15","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1126\/science.aaa8172","article-title":"The future of immune checkpoint therapy","volume":"348","author":"Sharma","year":"2015","journal-title":"Science"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1177\/0897190019850929","article-title":"Programmed cell death-1 monoclonal antibody therapy and type 1 diabetes mellitus: A review of the literature","volume":"34","author":"Farina","year":"2021","journal-title":"J Pharm Pract"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2018.09.040","article-title":"Pdl1 is expressed in the islets of people with type 1 diabetes and is up-regulated by interferons-alpha and-gamma via irf1 induction","volume":"36","author":"Colli","year":"2018","journal-title":"Ebiomedicine"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.2174\/1573399816666200330145501","article-title":"Vaccines for type 1 diabetes: Prevention or reversal","volume":"17","author":"Desai","year":"2021","journal-title":"Curr Diabetes Rev"},{"key":"B19","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1007\/BF01715857","article-title":"Efficacy of prednisone to induce remission in recent onset type i (insulin dependent) diabetic patients","volume":"65","author":"Secchi","year":"1987","journal-title":"Klin wochenschr"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1177\/193229680800200408","article-title":"Use of continuous glucose monitoring to estimate insulin requirements in patients with type 1 diabetes mellitus during a short course of prednisone","volume":"2","author":"Bevier","year":"2008","journal-title":"J Diabetes Sci Technol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"7014","DOI":"10.1038\/s41467-021-27276-7","article-title":"Comprehensive targeting of resistance to inhibition of rtk signaling pathways by using glucocorticoids","volume":"12","author":"Gong","year":"2021","journal-title":"Nat Commun"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1093\/eurpub\/ckaa166.591","article-title":"Azathioprine in the maintainance remission in inflammatory bowel disease patients: 7-year follow up","volume":"30","author":"Cassieri","year":"2020","journal-title":"Eur J Public Health"},{"key":"B23","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1056\/NEJM198809083191002","article-title":"Immunosuppression with azathioprine and prednisone in recent-onset insulin-dependent diabetes mellitus","volume":"319","author":"Silverstein","year":"1988","journal-title":"N Engl J Med"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1210\/js.2019-SUN-275","article-title":"Sun-275 azathioprine for tertiary prevention of diabetes in patients with newly diagnosed type 1 diabetes","volume":"3","author":"Geliebter","year":"2019","journal-title":"J Endocrine Soc"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3476(87)80058-6","article-title":"Effects of cyclosporine in recent-onset juvenile type 1 diabetes: impact of age and duration of disease","volume":"111","author":"Stiller","year":"1987","journal-title":"J Pediatr"},{"key":"B26","doi-asserted-by":"publisher","first-page":"e29","DOI":"10.2337\/dc07-2202","article-title":"Insulin resistance and progression to type 1 diabetes in the european nicotinamide diabetes intervention trial (endit): Response to bingley et al","volume":"31","author":"Wilkin","year":"2008","journal-title":"Diabetes Care"},{"key":"B27","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1146\/annurev.immunol.14.1.483","article-title":"Immunopharmacology of rapamycin","volume":"14","author":"Abraham","year":"1996","journal-title":"Annu Rev Immunol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-010-1959-6","article-title":"Beta cell function during rapamycin monotherapy in long-term type 1 diabetes","volume":"54","author":"Piemonti","year":"2011","journal-title":"Diabetologia"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.2337\/db08-1432","article-title":"Rapamycin prevents and breaks the anti-cd3-induced tolerance in nod mice","volume":"58","author":"Valle","year":"2009","journal-title":"Diabetes"},{"key":"B30","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1101\/gad.340919.120","article-title":"Mtor inhibition acts as an unexpected checkpoint in p53-mediated tumor suppression","volume":"35","author":"Kon","year":"2021","journal-title":"Genes Dev"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.2754-19.2020","article-title":"Microglial mtor is neuronal protective and antiepileptogenic in the pilocarpine model of temporal lobe epilepsy","volume":"40","author":"Zhao","year":"2020","journal-title":"J Neurosc"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.molimm.2016.01.008","article-title":"Rapamycin\/gaba combination treatment ameliorates diabetes in nod mice","volume":"73","author":"He","year":"2016","journal-title":"Mol Immunol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1402540","article-title":"Combination therapy using il-2\/il-2 monoclonal antibody complexes, rapamycin, and islet autoantigen peptides increases regulatory t cell frequency and protects against spontaneous and induced type 1 diabetes in nonobese diabetic mice","volume":"195","author":"Manirarora","year":"2015","journal-title":"J Immunol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1038\/s41551-021-00791-0","article-title":"Metabolic and immunomodulatory control of type 1 diabetes via orally delivered bile-acid-polymer nanocarriers of insulin or rapamycin","volume":"5","author":"Lee","year":"2021","journal-title":"Nat BioMed Eng"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa012864","article-title":"Anti-cd3 monoclonal antibody in new-onset type 1 diabetes mellitus","volume":"346","author":"Herold","year":"2002","journal-title":"N Engl J Med"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1172\/JCI27191","article-title":"Anti-cd3 and nasal proinsulin combination therapy enhances remission from recent-onset autoimmune diabetes by inducing tregs","volume":"116","author":"Bresson","year":"2006","journal-title":"J Clin Invest"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01103","article-title":"Intestinal delivery of proinsulin and il-10 via lactococcus lactis combined with low-dose anti-cd3 restores tolerance outside the window of acute type 1 diabetes diagnosis","volume":"11","author":"Cook","year":"2020","journal-title":"Front Immunol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1021\/acsbiomaterials.0c01075","article-title":"Combination treatment with antigen-specific dual-sized microparticle system plus anti-cd3 immunotherapy fails to synergize to improve late-stage type 1 diabetes prevention in nonobese diabetic mice","volume":"6","author":"Stewart","year":"2020","journal-title":"ACS Biomat Sci Eng"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.178.5.2883","article-title":"Tumor evasion of the immune system by converting cd4+cd25- t cells into cd4+cd25+ t regulatory cells: role of tumor-derived tgf-beta","volume":"178","author":"Liu","year":"2007","journal-title":"J Immunol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1038\/nrd3402","article-title":"Immunomodulatory therapy to preserve pancreatic beta-cell function in type 1 diabetes","volume":"10","author":"Waldron-Lynch","year":"2011","journal-title":"Nat Rev Drug Discovery"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.653088","article-title":"Immunosuppressive plga tgf-beta1 microparticles induce polyclonal and antigen-specific regulatory t cells for local immunomodulation of allogeneic islet transplants","volume":"12","author":"Li","year":"2021","journal-title":"Front Immunol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1834400100","article-title":"Cd4+cd25+ t regulatory cells control anti-islet cd8+ t cells through tgf-beta-tgf-beta receptor interactions in type 1 diabetes","volume":"100","author":"Green","year":"2003","journal-title":"Proc Natl Acad Sci u s"},{"key":"B43","doi-asserted-by":"publisher","first-page":"13027","DOI":"10.1038\/ncomms13027","article-title":"Loss of immune tolerance to il-2 in type 1 diabetes","volume":"7","author":"Perol","year":"2016","journal-title":"Nat Commun"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2015.11.065","article-title":"Transforming growth factor-beta 1 delivery from microporous scaffolds decreases inflammation post-implant and enhances function of transplanted islets","volume":"80","author":"Liu","year":"2016","journal-title":"Biomaterials"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2017.01.019","article-title":"Tgf-beta engineered mesenchymal stem cells (tgf-beta\/mscs) for treatment of type 1 diabetes (t1d) mice model","volume":"44","author":"Daneshmandi","year":"2017","journal-title":"Int immunopharmacol"},{"key":"B46","doi-asserted-by":"publisher","first-page":"172721","DOI":"10.1016\/j.ejphar.2019.172721","article-title":"Orally delivered all-trans-retinoic acid- and transforming growth factor-beta-loaded microparticles ameliorate type 1 diabetes in mice","volume":"864","author":"Koprivica","year":"2019","journal-title":"Eur J Pharmacol"},{"key":"B47","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/S2213-8587(13)70113-X","article-title":"Low-dose interleukin 2 in patients with type 1 diabetes: A phase 1\/2 randomised, double-blind, placebo-controlled trial","volume":"1","author":"Hartemann","year":"2013","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2008.03.016","article-title":"Central role of defective interleukin-2 production in the triggering of islet autoimmune destruction","volume":"28","author":"Tang","year":"2008","journal-title":"Immunity"},{"key":"B49","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.jaut.2015.01.001","article-title":"Low-dose interleukin-2 fosters a dose-dependent regulatory t cell tuned milieu in t1d patients","volume":"58","author":"Rosenzwajg","year":"2015","journal-title":"J autoimmun"},{"key":"B50","doi-asserted-by":"publisher","first-page":"e1002139","DOI":"10.1371\/journal.pmed.1002139","article-title":"Regulatory t cell responses in participants with type 1 diabetes after a single dose of interleukin-2: A non-randomised, open label, adaptive dose-finding trial","volume":"13","author":"TODD","year":"2016","journal-title":"PLoS Med"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1126\/science.1122927","article-title":"Selective stimulation of t cell subsets with antibody-cytokine immune complexes","volume":"311","author":"Boyman","year":"2006","journal-title":"Science"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2015.04.015","article-title":"Antibodies to interleukin-2 elicit selective t cell subset potentiation through distinct conformational mechanisms","volume":"42","author":"Spangler","year":"2015","journal-title":"Immunity"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0070-2","article-title":"A human anti-il-2 antibody that potentiates regulatory t cells by a structure-based mechanism","volume":"24","author":"Trotta","year":"2018","journal-title":"Nat Med"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abb9283","article-title":"Receptor-gated il-2 delivery by an anti-human il-2 antibody activates regulatory t cells in three different species","volume":"12","author":"Karakus","year":"2020","journal-title":"Sci Transl Med"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2015.04.018","article-title":"Interleukin-2 activity can be fine tuned with engineered receptor signaling clamps","volume":"42","author":"Mitra","year":"2015","journal-title":"Immunity"},{"key":"B56","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1146\/annurev-med-073118-011031","article-title":"Engineering il-2 to give new life to t cell immunotherapy","volume":"72","author":"Overwijk","year":"2021","journal-title":"Annu Rev Med"},{"key":"B57","doi-asserted-by":"publisher","first-page":"8106","DOI":"10.1038\/s41598-018-26161-6","article-title":"Treatment of t1d via optimized expansion of antigen-specific tregs induced by il-2\/anti-il-2 monoclonal antibody complexes and peptide\/mhc tetramers","volume":"8","author":"Izquierdo","year":"2018","journal-title":"Sci Rep"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1126\/science.aar3246","article-title":"Selective targeting of engineered t cells using orthogonal il-2 cytokine-receptor complexes","volume":"359","author":"Sockolosky","year":"2018","journal-title":"Science"},{"key":"B59","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1038\/nm730","article-title":"Tumor-associated b7-h1 promotes t-cell apoptosis: A potential mechanism of immune evasion","volume":"8","author":"Dong","year":"2002","journal-title":"Nat Med"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1002\/eji.200425274","article-title":"Interleukin-2 is essential for cd4+cd25+ regulatory t cell function","volume":"34","author":"De La Rosa","year":"2004","journal-title":"Eur J Immunol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-017-2033-8","article-title":"Autoimmune diabetes induced by pd-1 inhibitor-retrospective analysis and pathogenesis: A case report and literature review","volume":"66","author":"Gauci","year":"2017","journal-title":"Cancer Immunol Immunother"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20022125","article-title":"The programmed death-1 (pd-1) pathway regulates autoimmune diabetes in nonobese diabetic (nod) mice","volume":"198","author":"Ansari","year":"2003","journal-title":"J Exp Med"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.2337\/db12-1475","article-title":"Pd-1, but not pd-l1, expressed by islet-reactive cd4+ t cells suppresses infiltration of the pancreas during type 1 diabetes","volume":"62","author":"Pauken","year":"2013","journal-title":"Diabetes"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.2337\/dc14-2349","article-title":"Precipitation of autoimmune diabetes with anti-pd-1 immunotherapy","volume":"38","author":"Hughes","year":"2015","journal-title":"Diabetes Care"},{"key":"B65","doi-asserted-by":"publisher","first-page":"caam75","DOI":"10.1126\/scitranslmed.aam7543","article-title":"PD-L1 genetic overexpression or pharmacological restoration in hematopoietic stem and progenitor cells reverses autoimmune diabetes","volume":"9","author":"Ben Nasr","year":"2017","journal-title":"Sci Transl Med"},{"key":"B66","doi-asserted-by":"publisher","first-page":"e1907692","DOI":"10.1002\/adma.201907692","article-title":"Engineered pd-l1-expressing platelets reverse new-onset type 1 diabetes","volume":"32","author":"Zhang","year":"2020","journal-title":"Adv mat"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2631-z","article-title":"Immune-evasive human islet-like organoids ameliorate diabetes","volume":"586","author":"Yoshihara","year":"2020","journal-title":"Nature"},{"key":"B68","doi-asserted-by":"publisher","first-page":"19990","DOI":"10.1021\/acsnano.1c07538","article-title":"In vivo bioengineering of beta cells with immune checkpoint ligand as a treatment for early-onset type 1 diabetes mellitus","volume":"15","author":"Au","year":"2021","journal-title":"ACS nano"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.2337\/dbi18-0002","article-title":"Collateral damage: Insulin-dependent diabetes induced with checkpoint inhibitors","volume":"67","author":"Stamatouli","year":"2018","journal-title":"Diabetes"},{"key":"B70","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1016\/j.ccell.2018.09.008","article-title":"Emerging concepts for immune checkpoint blockade-based combination therapies","volume":"34","author":"Zappasodi","year":"2018","journal-title":"Cancer Cell"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1038\/ni846","article-title":"Ctla-4-ig regulates tryptophan catabolism in vivo","volume":"3","author":"Grohmann","year":"2002","journal-title":"Nat Immunol"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1038\/gt.2015.18","article-title":"Beta-cell-targeted blockage of pd1 and ctla4 pathways prevents development of autoimmune diabetes and acute allogeneic islets rejection","volume":"22","author":"El Khatib","year":"2015","journal-title":"Gene Ther"},{"key":"B73","doi-asserted-by":"publisher","first-page":"13193","DOI":"10.1038\/ncomms13193","article-title":"Photothermal therapy with immune-adjuvant nanoparticles together with checkpoint blockade for effective cancer immunotherapy","volume":"7","author":"Chen","year":"2016","journal-title":"Nat Commun"},{"key":"B74","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1038\/s41419-022-04520-6","article-title":"Galectin-1 confers resistance to doxorubicin in hepatocellular carcinoma cells through modulation of p-glycoprotein expression","volume":"13","author":"Carabias","year":"2022","journal-title":"Cell Death Dis"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v23.i29.5266","article-title":"Contribution of galectin-1, a glycan-binding protein, to gastrointestinal tumor progression","volume":"23","author":"Bacigalupo","year":"2017","journal-title":"World J Gastroenterol"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1701172","article-title":"Galectin-1: A jack-of-all-trades in the resolution of acute and chronic inflammation","volume":"199","author":"Sundblad","year":"2017","journal-title":"J Immunol"},{"key":"B77","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.canlet.2021.04.011","article-title":"The tim3\/gal9 signaling pathway: An emerging target for cancer immunotherapy","volume":"510","author":"Kandel","year":"2021","journal-title":"Cancer Lett"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2017.01.006","article-title":"Tim3\/gal9 interactions between t cells and monocytes result in an immunosuppressive feedback loop that inhibits th1 responses in osteosarcoma patients","volume":"44","author":"Li","year":"2017","journal-title":"Int immunopharmacol"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1210\/en.2014-1374","article-title":"Galectin-3 activates ppargamma and supports white adipose tissue formation and high-fat diet-induced obesity","volume":"156","author":"Baek","year":"2015","journal-title":"Endocrinology"},{"key":"B80","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1016\/j.cell.2016.10.025","article-title":"Hematopoietic-derived galectin-3 causes cellular and systemic insulin resistance","volume":"167","author":"Li","year":"2016","journal-title":"Cell"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2010.09.020","article-title":"Galectin-3 ablation protects mice from diet-induced nash: a major scavenging role for galectin-3 in liver","volume":"54","author":"Iacobini","year":"2011","journal-title":"J Hepatol"},{"key":"B82","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1007\/s13167-010-0009-2","article-title":"The potential role of indoleamine 2,3 dioxygenase (ido) as a predictive and therapeutic target for diabetes treatment: A mythical truth","volume":"1","author":"Baban","year":"2010","journal-title":"Epma J"},{"key":"B83","doi-asserted-by":"publisher","first-page":"3489","DOI":"10.1038\/s41467-022-31126-5","article-title":"Adipocyte-derived kynurenine promotes obesity and insulin resistance by activating the ahr\/stat3\/il-6 signaling","volume":"13","author":"Huang","year":"2022","journal-title":"Nat Commun"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.2337\/db17-1281","article-title":"Loss of ido1 expression from human pancreatic beta-cells precedes their destruction during the development of type 1 diabetes","volume":"67","author":"Anquetil","year":"2018","journal-title":"Diabetes"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0901577","article-title":"Ido mediates tlr9-driven protection from experimental autoimmune diabetes","volume":"183","author":"Fallarino","year":"2009","journal-title":"J Immunol"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1111\/jcmm.12360","article-title":"Forced ido1 expression in dendritic cells restores immunoregulatory signalling in autoimmune diabetes","volume":"18","author":"Pallotta","year":"2014","journal-title":"J Cell Mol Med"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.00428","article-title":"The proteasome inhibitor bortezomib controls indoleamine 2,3-dioxygenase 1 breakdown and restores immune regulation in autoimmune diabetes","volume":"8","author":"Mondanelli","year":"2017","journal-title":"Front Immunol"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.25301","article-title":"Ido-expressing fibroblasts protect islet beta cells from immunological attack and reverse hyperglycemia in non-obese diabetic mice","volume":"231","author":"Zhang","year":"2016","journal-title":"J Cell Physiol"},{"key":"B89","unstructured":"Oral probiotic VSL#3 prevents autoimmune diabetes by modulating microbiota and promoting indoleamine 2,3-dioxygenase-enriched tolerogenic intestinal environment7569431 DolpadyJ SoriniC Di PietroC CosorichI FerrareseR SaitaD 10.1155\/2016\/7569431J Diabetes Res20162016"},{"key":"B90","doi-asserted-by":"crossref","DOI":"10.4049\/jimmunol.155.3.1151","article-title":"Immunologic self-tolerance maintained by activated t cells expressing il-2 receptor alpha-chains (cd25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases","volume":"155","author":"Sakaguchi","year":"1995","journal-title":"J Immunol"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1038\/ni904","article-title":"Foxp3 programs the development and function of cd4+cd25+ regulatory t cells","volume":"4","author":"Fontenot","year":"2003","journal-title":"Nat Immunol"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1172\/JCI67226","article-title":"Harnessing foxp3+ regulatory t cells for transplantation tolerance","volume":"124","author":"Waldmann","year":"2014","journal-title":"J Clin Invest"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1016\/j.smim.2003.12.009","article-title":"Regulatory t cells generated ex vivo as an approach for the therapy of autoimmune disease","volume":"16","author":"Horwitz","year":"2004","journal-title":"Semin Immunol"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/dxh122","article-title":"Induction of antigen-specific immunologic tolerance by in vivo and in vitro antigen-specific expansion of naturally arising foxp3+cd25+cd4+ regulatory t cells","volume":"16","author":"Nishimura","year":"2004","journal-title":"Int Immunol"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.2337\/db08-1168","article-title":"Expansion of human regulatory t-cells from patients with type 1 diabetes","volume":"58","author":"Putnam","year":"2009","journal-title":"Diabetes"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1111\/j.0105-2896.2006.00422.x","article-title":"Dendritic cells expand antigen-specific foxp3+ cd25+ cd4+ regulatory t cells including suppressors of alloreactivity","volume":"212","author":"Yamazaki","year":"2006","journal-title":"Immunol Rev"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20040180","article-title":"Cd25+ cd4+ t cells, expanded with dendritic cells presenting a single autoantigenic peptide, suppress autoimmune diabetes","volume":"199","author":"Tarbell","year":"2004","journal-title":"J Exp Med"},{"key":"B98","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1084\/jem.20061631","article-title":"Dendritic cell-expanded, islet-specific cd4+ cd25+ cd62l+ regulatory t cells restore normoglycemia in diabetic nod mice","volume":"204","author":"Tarbell","year":"2007","journal-title":"J Exp Med"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20060772","article-title":"Cd127 expression inversely correlates with foxp3 and suppressive function of human cd4+ t reg cells","volume":"203","author":"Liu","year":"2006","journal-title":"J Exp Med"},{"key":"B100","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.clim.2014.03.016","article-title":"Therapy of type 1 diabetes with cd4(+)cd25(high)cd127-regulatory t cells prolongs survival of pancreatic islets - results of one year follow-up","volume":"153","author":"Marek-Trzonkowska","year":"2014","journal-title":"Clin Immunol"},{"key":"B101","doi-asserted-by":"publisher","first-page":"315ra189","DOI":"10.1126\/scitranslmed.aad4134","article-title":"Type 1 diabetes immunotherapy using polyclonal regulatory t cells","volume":"7","author":"Bluestone","year":"2015","journal-title":"Sci Transl Med"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.2337\/dc12-0038","article-title":"Administration of cd4+cd25highcd127- regulatory t cells preserves beta-cell function in type 1 diabetes in children","volume":"35","author":"Marek-Trzonkowska","year":"2012","journal-title":"Diabetes Care"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.126471","article-title":"Stem cell-derived tissue-associated regulatory t cells suppress the activity of pathogenic cells in autoimmune diabetes","volume":"4","author":"Haque","year":"2019","journal-title":"JCI Insight"},{"key":"B104","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1097\/SLA.0b013e31822c9ca7","article-title":"Coating human pancreatic islets with cd4(+)cd25(high)cd127(-) regulatory t cells as a novel approach for the local immunoprotection","volume":"254","author":"Marek","year":"2011","journal-title":"Ann Surg"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1016\/j.transproceed.2014.05.075","article-title":"Improved coating of pancreatic islets with regulatory t cells to create local immunosuppression by using the biotin-polyethylene glycol-succinimidyl valeric acid ester molecule","volume":"46","author":"Golab","year":"2014","journal-title":"Transplant Proc"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.2337\/db19-0061","article-title":"Immunomodulation followed by antigen-specific treg infusion controls islet autoimmunity","volume":"69","author":"Cabello-Kindelan","year":"2020","journal-title":"Diabetes"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.01313","article-title":"Avidity and bystander suppressive capacity of human regulatory t cells expressing de novo autoreactive t-cell receptors in type 1 diabetes","volume":"8","author":"Yeh","year":"2017","journal-title":"Front Immunol"},{"key":"B108","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.jaut.2017.01.001","article-title":"Generation of human islet-specific regulatory t cells by tcr gene transfer","volume":"79","author":"Hull","year":"2017","journal-title":"J autoimmun"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1172\/JCI82771","article-title":"Alloantigen-specific regulatory t cells generated with a chimeric antigen receptor","volume":"126","author":"Macdonald","year":"2016","journal-title":"J Clin Invest"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.92865","article-title":"T Cells expressing chimeric antigen receptor promote immune tolerance","volume":"2","author":"Pierini","year":"2017","journal-title":"JCI Insight"},{"key":"B111","doi-asserted-by":"publisher","first-page":"102289","DOI":"10.1016\/j.jaut.2019.05.017","article-title":"Regulatory t cells engineered with a novel insulin-specific chimeric antigen receptor as a candidate immunotherapy for type 1 diabetes","volume":"103","author":"Tenspolde","year":"2019","journal-title":"J autoimmun"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-016-1953-z","article-title":"Immunosuppressive myeloid-derived suppressor cells are increased in splenocytes from cancer patients","volume":"66","author":"Jordan","year":"2017","journal-title":"Cancer Immunol Immunother"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.798320","article-title":"Emerging roles of myeloid-derived suppressor cells in diabetes","volume":"12","author":"Wang","year":"2021","journal-title":"Front Pharmacol"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1002\/eji.201444522","article-title":"Human fibrocytic myeloid-derived suppressor cells express ido and promote tolerance via treg-cell expansion","volume":"44","author":"Zoso","year":"2014","journal-title":"Eur J Immunol"},{"key":"B115","doi-asserted-by":"publisher","first-page":"e100013","DOI":"10.1371\/journal.pone.0100013","article-title":"Evaluation of the therapeutic potential of bone marrow-derived myeloid suppressor cell (mdsc) adoptive transfer in mouse models of autoimmunity and allograft rejection","volume":"9","author":"Drujont","year":"2014","journal-title":"PLoS One"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2014.04.006","article-title":"Myeloid-derived suppressor cells are increased in frequency but not maximally suppressive in peripheral blood of type 1 diabetes mellitus patients","volume":"153","author":"Whitfield-Larry","year":"2014","journal-title":"Clin Immunol"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0000000000001529","article-title":"C-c chemokine receptor type 2-dependent migration of myeloid-derived suppressor cells in protection of islet transplants","volume":"101","author":"Qin","year":"2017","journal-title":"Transplantation"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0000000000001529","article-title":"Dendritic cells and macrophages are the first and major producers of tnf-alpha in pancreatic islets in the nonobese diabetic mouse","volume":"160","author":"Dahlen","year":"1998","journal-title":"J Immunol"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1172\/JCI59643","article-title":"Macrophage plasticity and polarization: in vivo veritas","volume":"122","author":"Sica","year":"2012","journal-title":"J Clin Invest"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1172\/JCI36150","article-title":"Macrophage diversity in renal injury and repair","volume":"118","author":"Ricardo","year":"2008","journal-title":"J Clin Invest"},{"key":"B121","doi-asserted-by":"publisher","first-page":"485","DOI":"10.3390\/metabo10120485","article-title":"Good cop, bad cop: The opposing effects of macrophage activation state on maintaining or damaging functional beta-cell mass","volume":"10","author":"Jensen","year":"2020","journal-title":"Metabolites"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1159\/000321034","article-title":"Transfused macrophages ameliorate pancreatic and renal injury in murine diabetes mellitus","volume":"118","author":"Zheng","year":"2011","journal-title":"Nephron Exp Nephrol"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.2337\/db11-1635","article-title":"Adoptive transfer of immunomodulatory m2 macrophages prevents type 1 diabetes in nod mice","volume":"61","author":"Parsa","year":"2012","journal-title":"Diabetes"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1111\/jcmm.13983","article-title":"Exploring macrophage cell therapy on diabetic kidney disease","volume":"23","author":"Guiteras","year":"2019","journal-title":"J Cell Mol Med"},{"key":"B125","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1007\/s12026-019-09072-0","article-title":"Monocytes of newly diagnosed juvenile dm1 patients are prone to differentiate into regulatory il-10(+) m2 macrophages","volume":"67","author":"Juhas","year":"2019","journal-title":"Immunol Res"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1196\/annals.1375.021","article-title":"Viruses cause type 1 diabetes in animals","volume":"1079","author":"Yoon","year":"2006","journal-title":"Ann n y Acad Sci"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1097\/QCO.0b013e3283608300","article-title":"Enteroviral pathogenesis of type 1 diabetes: queries and answers","volume":"26","author":"Hober","year":"2013","journal-title":"Curr Opin Infect Dis"},{"key":"B128","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.virol.2005.09.015","article-title":"One hundred years of poliovirus pathogenesis","volume":"344","author":"Racaniello","year":"2006","journal-title":"Virology"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1083\/jcb.201803061","article-title":"Metabolic regulation of chromatin modifications and gene expression","volume":"217","author":"Schvartzman","year":"2018","journal-title":"J Cell Biol"},{"key":"B130","doi-asserted-by":"publisher","first-page":"3622","DOI":"10.1038\/s41598-022-07603-8","article-title":"Bordetella pertussis-infected innate immune cells drive the anti-pertussis response of human airway epithelium","volume":"12","author":"Kroes","year":"2022","journal-title":"Sci Rep"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1203\/00006450-198402000-00021","article-title":"The effect of pertussis vaccine on the insulin-dependent diabetes induced by streptozotocin in mice","volume":"18","author":"Huang","year":"1984","journal-title":"Pediatr Res"},{"key":"B132","doi-asserted-by":"publisher","first-page":"103150","DOI":"10.1016\/j.isci.2021.103150","article-title":"Bacillus calmette-guerin 's beneficial impact on glucose metabolism: Evidence for broad based applications","volume":"24","author":"Shpilsky","year":"2021","journal-title":"Iscience"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.2337\/db09-0451","article-title":"Antigen-based therapy for the treatment of type 1 diabetes","volume":"58","author":"Tian","year":"2009","journal-title":"Diabetes"},{"key":"B134","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/S1357-4310(99)01450-1","article-title":"Q fever vaccine on trial for type i diabetes","volume":"5","author":"Bonn","year":"1999","journal-title":"Mol Med Today"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.1172\/JCI5857","article-title":"Ctla4ig-mediated blockade of t-cell costimulation in patients with psoriasis vulgaris","volume":"103","author":"Abrams","year":"1999","journal-title":"J Clin Invest"},{"key":"B136","doi-asserted-by":"publisher","first-page":"101085","DOI":"10.1016\/j.isci.2020.101085","article-title":"Bcg vaccinations upregulate myc, a central switch for improved glucose metabolism in diabetes","volume":"23","author":"Kuhtreiber","year":"2020","journal-title":"Iscience"},{"key":"B137","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1038\/s41541-022-00466-0","article-title":"Self-adjuvanting nanovaccines boost lung-resident cd4(+) t cell immune responses in bcg-primed mice","volume":"7","author":"Files","year":"2022","journal-title":"NPJ Vaccines"},{"key":"B138","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1038\/s41541-018-0062-8","article-title":"Long-term reduction in hyperglycemia in advanced type 1 diabetes: The value of induced aerobic glycolysis with bcg vaccinations","volume":"3","author":"Kuhtreiber","year":"2018","journal-title":"NPJ Vaccines"},{"key":"B139","doi-asserted-by":"publisher","first-page":"22037","DOI":"10.1038\/s41598-021-01549-z","article-title":"Rotavirus spike protein deltavp8* as a novel carrier protein for conjugate vaccine platform with demonstrated antigenic potential for use as bivalent vaccine","volume":"11","author":"Park","year":"2021","journal-title":"Sci Rep"},{"key":"B140","doi-asserted-by":"publisher","first-page":"7727","DOI":"10.1038\/s41598-019-44193-4","article-title":"Lower incidence rate of type 1 diabetes after receipt of the rotavirus vaccine in the united states 2001-2017","volume":"9","author":"Rogers","year":"2019","journal-title":"Sci Rep"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2009.197","article-title":"Genetic-induced variations in the gad65 t-cell repertoire governs efficacy of anti-cd3\/gad65 combination therapy in new-onset type 1 diabetes","volume":"18","author":"Bresson","year":"2010","journal-title":"Mol Ther"},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.1016\/S1525-0016(03)00063-7","article-title":"Dna vaccination against mutant huntingtin ameliorates the hdr6\/2 diabetic phenotype","volume":"7","author":"Miller","year":"2003","journal-title":"Mol Ther"},{"key":"B143","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.27.10.2348","article-title":"Pancreatic beta-cell function and immune responses to insulin after administration of intranasal insulin to humans at risk for type 1 diabetes","volume":"27","author":"Harrison","year":"2004","journal-title":"Diabetes Care"},{"key":"B144","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-014-3436-0","article-title":"A preclinical study on the efficacy and safety of a new vaccine against coxsackievirus b1 reveals no risk for accelerated diabetes development in mouse models","volume":"58","author":"Larsson","year":"2015","journal-title":"Diabetologia"},{"key":"B145","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.1996.tb21144.x","article-title":"Active suppression of diabetes after oral administration of insulin is determined by antigen dosage","volume":"778","author":"Bergerot","year":"1996","journal-title":"Ann n y Acad Sci"},{"key":"B146","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtm.2018.12.002","article-title":"Preproinsulin designer antigens excluded from endoplasmic reticulum suppressed diabetes development in nod mice by dna vaccination","volume":"12","author":"Stifter","year":"2019","journal-title":"Mol Ther Methods Clin Dev"},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2006.03.021","article-title":"Protective regulatory t cell generation in autoimmune diabetes by dna covaccination with islet antigens and a selective ctla-4 ligand","volume":"14","author":"Glinka","year":"2006","journal-title":"Mol Ther"},{"key":"B148","doi-asserted-by":"publisher","first-page":"3858","DOI":"10.1038\/s41598-019-40325-y","article-title":"Peptide vaccine for semaphorin3e ameliorates systemic glucose intolerance in mice with dietary obesity","volume":"9","author":"Yoshida","year":"2019","journal-title":"Sci Rep"},{"key":"B149","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1089\/10430340252792521","article-title":"Immunoinhibitory dna vaccine protects against autoimmune diabetes through cdna encoding a selective ctla-4 (cd152) ligand","volume":"13","author":"Prud'homme","year":"2002","journal-title":"Hum Gene Ther"},{"key":"B150","doi-asserted-by":"publisher","DOI":"10.1038\/sj.gt.3302578","article-title":"Dna vaccination with an insulin construct and a chimeric protein binding to both ctla4 and cd40 ameliorates type 1 diabetes in nod mice","volume":"12","author":"Chang","year":"2005","journal-title":"Gene Ther"},{"key":"B151","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2249.2008.03814.x","article-title":"Proinsulin peptide immunotherapy in type 1 diabetes: Report of a first-in-man phase i safety study","volume":"155","author":"Thrower","year":"2009","journal-title":"Clin Exp Immunol"},{"key":"B152","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2012.190","article-title":"Nonviral delivery of small interfering rna into pancreas-associated immune cells prevents autoimmune diabetes","volume":"20","author":"Leconet","year":"2012","journal-title":"Mol Ther"},{"key":"B153","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2016.12.007","article-title":"Adoptive transfer of mrna-transfected t cells redirected against diabetogenic cd8 t cells can prevent diabetes","volume":"25","author":"Fishman","year":"2017","journal-title":"Mol Ther"},{"key":"B154","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1016\/j.cmet.2020.12.019","article-title":"Mir-690, an exosomal-derived mirna from m2-polarized macrophages, improves insulin sensitivity in obese mice","volume":"33","author":"Ying","year":"2021","journal-title":"Cell Metab"},{"key":"B155","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.711","article-title":"Heat-shock protein peptide diapep277 treatment in children with newly diagnosed type 1 diabetes: a randomised, double-blind phase ii study","volume":"23","author":"Lazar","year":"2007","journal-title":"Diabetes Metab Res Rev"},{"key":"B156","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.712","article-title":"Treatment of new-onset type 1 diabetes with peptide diapep277 is safe and associated with preserved beta-cell function: extension of a randomized, double-blind, phase ii trial","volume":"23","author":"Raz","year":"2007","journal-title":"Diabetes Metab Res Rev"},{"key":"B157","doi-asserted-by":"publisher","DOI":"10.1084\/jem.183.4.1561","article-title":"Nasal administration of glutamate decarboxylase (gad65) peptides induces th2 responses and prevents murine insulin-dependent diabetes","volume":"183","author":"Tian","year":"1996","journal-title":"J Exp Med"},{"key":"B158","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdiacomp.2004.12.003","article-title":"Clinical evidence for the safety of gad65 immunomodulation in adult-onset autoimmune diabetes","volume":"19","author":"Agardh","year":"2005","journal-title":"J Diabetes Complicat"},{"key":"B159","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.neuint.2009.01.020","article-title":"A novel mechanism for gaba synthesis and packaging into synaptic vesicles","volume":"55","author":"Buddhala","year":"2009","journal-title":"Neurochem Int"},{"key":"B160","doi-asserted-by":"publisher","DOI":"10.1038\/s41578-019-0112-5","article-title":"Engineering immunomodulatory biomaterials for type 1 diabetes","volume":"4","author":"Stabler","year":"2019","journal-title":"Nat Rev mat"},{"key":"B161","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2019.07.013","article-title":"Icos costimulation at the tumor site in combination with ctla-4 blockade therapy elicits strong tumor immunity","volume":"27","author":"Soldevilla","year":"2019","journal-title":"Mol Ther"},{"key":"B162","doi-asserted-by":"publisher","first-page":"13155","DOI":"10.1038\/srep13155","article-title":"A combination hydrogel microparticle-based vaccine prevents type 1 diabetes in non-obese diabetic mice","volume":"5","author":"Yoon","year":"2015","journal-title":"Sci Rep"},{"key":"B163","doi-asserted-by":"publisher","DOI":"10.1586\/14760584.2014.933078","article-title":"Developing a vaccine for type 1 diabetes through targeting enteroviral infections","volume":"13","author":"Hyoty","year":"2014","journal-title":"Expert Rev Vaccines"},{"key":"B164","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2015.227","article-title":"Development of an interleukin-1beta vaccine in patients with type 2 diabetes","volume":"24","author":"Cavelti-Weder","year":"2016","journal-title":"Mol Ther"},{"key":"B165","doi-asserted-by":"publisher","first-page":"14048","DOI":"10.1038\/mtm.2014.48","article-title":"Preclinical efficacy and safety of an anti-il-1beta vaccine for the treatment of type 2 diabetes","volume":"1","author":"Spohn","year":"2014","journal-title":"Mol Ther Methods Clin Dev"},{"key":"B166","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2010.146","article-title":"A short pulse of il-4 delivered by dcs electroporated with modified mrna can both prevent and treat autoimmune diabetes in nod mice","volume":"18","author":"Creusot","year":"2010","journal-title":"Mol Ther"},{"key":"B167","doi-asserted-by":"publisher","DOI":"10.1016\/s1525-0016(16)45312-8","article-title":"1106. High proteasome activity is a common feature among stem cells of different lineages and restricts lentiviral gene transfer","volume":"15","author":"Santoni De Sio","year":"2007","journal-title":"Mol Ther"},{"key":"B168","doi-asserted-by":"publisher","first-page":"e2101253","DOI":"10.1002\/adma.202101253","article-title":"Immune checkpoint-bioengineered beta cell vaccine reverses early-onset type 1 diabetes","volume":"33","author":"Au","year":"2021","journal-title":"Adv mat"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.997287\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T00:13:56Z","timestamp":1678493636000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.997287\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,2]]},"references-count":168,"alternative-id":["10.3389\/fimmu.2022.997287"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.997287","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,2]]},"article-number":"997287"}}